2024年度,专注于高端肿瘤医疗领域的美中嘉和.HK,股价7.12港元,市值51亿港元)录得营收3.88亿元。2021年—2024年,美中嘉和营业收入分别为4.71亿元、4.77亿元、5.39亿元、3.88亿元。在3月31日召开的2024年度线上业绩会上,公司管理层坦陈,2024年是近几年中收入最低的一年,原因包括客观环境和主观结构调整。从2024年年度报告来看,美中嘉和短期内仍面临一定的财务压力...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.